Recently, two recent studies in patients with asthma suggested the involvement of interleukin‐6 (IL‐6) in the pathomechanism underlying exacerbations: In the first study, patients with high serum IL‐6 (> 1 pg/mL) had an increased exacerbation risk, whilst the second study demonstrated that a bronchial IL‐6 trans‐signalling (IL6TS) high expression profile, indicative of increased IL‐6 release, was also associated with more exacerbations [10, 11]. Here, IL6 is linked to asthma.